Ultragenyx Pharmaceutical, Inc. (RARE)
15.43
-0.14
(-0.90%)
USD |
NASDAQ |
Nov 06, 16:00
15.42
-0.01
(-0.06%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Cash from Investing (Quarterly) : 58.00M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 58.00M |
| June 30, 2026 | 44.00M |
| March 31, 2026 | -49.00M |
| December 31, 2025 | -72.25M |
| September 30, 2025 | 117.18M |
| June 30, 2025 | 71.18M |
| March 31, 2025 | 119.89M |
| December 31, 2024 | 102.74M |
| September 30, 2024 | -268.50M |
| June 30, 2024 | 60.56M |
| March 31, 2024 | 94.44M |
| December 31, 2023 | -107.02M |
| September 30, 2023 | 64.30M |
| June 30, 2023 | 99.42M |
| March 31, 2023 | 111.30M |
| December 31, 2022 | -171.60M |
| September 30, 2022 | -161.86M |
| June 30, 2022 | 79.17M |
| March 31, 2022 | -37.36M |
| December 31, 2021 | 69.06M |
| September 30, 2021 | -40.76M |
| June 30, 2021 | -41.25M |
| March 31, 2021 | -182.42M |
| December 31, 2020 | 97.90M |
| September 30, 2020 | -95.76M |
| Date | Value |
|---|---|
| June 30, 2020 | -86.14M |
| March 31, 2020 | -95.12M |
| December 31, 2019 | 67.27M |
| September 30, 2019 | 79.31M |
| June 30, 2019 | -58.43M |
| March 31, 2019 | -101.19M |
| December 31, 2018 | 73.56M |
| September 30, 2018 | 16.20M |
| June 30, 2018 | -52.07M |
| March 31, 2018 | -71.03M |
| December 31, 2017 | 57.10M |
| September 30, 2017 | 29.79M |
| June 30, 2017 | -21.08M |
| March 31, 2017 | -9.40M |
| December 31, 2016 | -9.616M |
| September 30, 2016 | 53.77M |
| June 30, 2016 | 23.99M |
| March 31, 2016 | 21.78M |
| December 31, 2015 | -33.56M |
| September 30, 2015 | -143.72M |
| June 30, 2015 | -111.01M |
| March 31, 2015 | -4.065M |
| December 31, 2014 | -17.02M |
| September 30, 2014 | -13.54M |
| June 30, 2014 | -27.48M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 23.50M |
| AbbVie, Inc. | -10.22B |
| Krystal Biotech, Inc. | -57.98M |
| BridgeBio Pharma, Inc. | 36.61M |
| Alnylam Pharmaceuticals, Inc. | -311.74M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -43.00M |
| Cash from Financing (Quarterly) | 10.00M |
| Free Cash Flow | -446.77M |
| Free Cash Flow Per Share (Quarterly) | -0.4407 |
| Free Cash Flow to Equity (Quarterly) | -29.00M |
| Free Cash Flow to Firm (Quarterly) | -26.42M |
| Free Cash Flow Yield | -28.63% |